Literature DB >> 19449473

[The network of methotrexate toxicity].

Clarinda Neves1, Rosa Jorge, Anabela Barcelos.   

Abstract

INTRODUCTION: Methotrexate is a folic acid antagonist recognised as one of the most important DMARD's in the rheumatoid arthritis treatment. Although the indisputable efficacy and the good tolerance profile, the broad toxicity spectrum is very variable with respect both to symptoms and intensity. The side effects vary from malaise and asthenia to pneumonitis or pancytopenia, which can be fatal.
OBJECTIVES: To review the adverse effects of methotrexate in the treatment of rheumatoid arthritis.
MATERIALS AND METHODS: Literature review, using Medline as a starting point, searching with the keywords "methotrexate", "toxic effects", "adverse effects", "rheumatoid arthritis". The relevant papers and selected references found therein were used.
RESULTS: The gastrointestinal symptoms are the most frequent, but myelossupression and pneumonitis are the most feared ones. Elevation of transaminases could indicate hepatic toxicity, placing the risk of cirrhosis. Cutaneous lesions, neurologic symptoms, changes in the bone metabolism, teratogenecity and hyperhomocysteinemia are other examples of the adverse effects of methotrexate. The post-dosing reactions are still not well known. The folate supplementation is important in the prevention of folate metabolism dependent symptoms. The farmacogenomics may help to identify patients in greater risk for multiple side effects.
CONCLUSIONS: Knowing and monitoring the methotrexate side effects is extremely important and should be carefully considered in order to prevent both therapeutic withdrawals due to toxicity as well as fatal outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449473

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  7 in total

1.  Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats.

Authors:  Venkatesan Saratha; Sorimuthu Pillai Subramanian
Journal:  Inflammopharmacology       Date:  2011-10-16       Impact factor: 4.473

2.  Preparation and assessment of chitosan-coated superparamagnetic Fe3O4 nanoparticles for controlled delivery of methotrexate.

Authors:  S Mohammadi-Samani; R Miri; M Salmanpour; N Khalighian; S Sotoudeh; N Erfani
Journal:  Res Pharm Sci       Date:  2013-01

3.  Efficacy and safety of methotrexate in alopecia areata.

Authors:  Mariana Hammerschmidt; Fabiane Mulinari Brenner
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

4.  Bilateral septic knee arthritis after treatment of an ectopic pregnancy with methotrexate.

Authors:  Fatih Karaaslan; Musa Uğur Mermerkaya; Emre Yurdakul; Özlem Tanın
Journal:  Int Med Case Rep J       Date:  2015-01-13

5.  Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study.

Authors:  Jaime C Branco; Anabela Barcelos; Filipe Pombo de Araújo; Graça Sequeira; Inês Cunha; José Vaz Patto; Margarida Oliveira; Margarida Pratas Mateus; Maura Couto; Patrícia Nero; Patrícia Pinto; Paulo Monteiro; Walter Castelão; Jorge Félix; Diana Ferreira; João Almeida; Maria João Silva
Journal:  Adv Ther       Date:  2016-01-02       Impact factor: 3.845

6.  Effect of Nigella sativa (black seeds) against methotrexate-induced nephrotoxicity in mice.

Authors:  Jawad Hassan Ahmed; Isra Mohammed Abdulmajeed
Journal:  J Intercult Ethnopharmacol       Date:  2016-12-22

7.  Methotrexate-induced pneumonitis in Crohn's disease. Case report and review of the literature.

Authors:  Nadia D'Andrea; Luca Triolo; Giovanna Margagnoni; Annalisa Aratari; Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2010-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.